Opus Genetics Secures Up To $155M Non-Dilutive Financing From Oberland Capital Plus 1.1M Shares At $4.48 To Advance Inherited Retinal Disease Gene Therapy Pipeline

Benzinga Newsdesk www.benzinga.com Positive 74.4%

Neg 0% Neu 0% Pos 74.4%

Comments

No comments yet. Be the first!